Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' EBITDA Margin rose 297400.0% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.7%, marking a year-over-year increase of 66000.0%. This contributed to the annual value of 1.3% for FY2024, which is 98900.0% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' EBITDA Margin stood at 15.91%, which was up 297400.0% from 6.57% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBITDA Margin registered a high of 27.19% during Q1 2021, and its lowest value of 38.94% during Q4 2021.
  • In the last 5 years, Ani Pharmaceuticals' EBITDA Margin had a median value of 3.74% in 2024 and averaged 1.32%.
  • The largest annual percentage gain for Ani Pharmaceuticals' EBITDA Margin in the last 5 years was 408700bps (2022), contrasted with its biggest fall of -569600bps (2022).
  • Ani Pharmaceuticals' EBITDA Margin (Quarter) stood at 38.94% in 2021, then skyrocketed by 105bps to 1.93% in 2022, then surged by 165bps to 5.11% in 2023, then plummeted by -145bps to 2.3% in 2024, then soared by 792bps to 15.91% in 2025.
  • Its EBITDA Margin was 15.91% in Q3 2025, compared to 6.57% in Q2 2025 and 13.29% in Q1 2025.